ArticleeLife2020
Protective role of neuronal and lymphoid cannabinoid CB
Open access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 44 citations in OpenAlex.
- FermentedPharmaceutical biology · 2026Article
- Assessments of Evoked and Spontaneous Pain Following Administration of Gabapentin and the Cannabinoid CBCannabis and cannabinoid research · 2026Article
- Small peptides derived from the autoinhibitory XY linker of phospholipase C-β isoforms inhibit enzyme activity and reduce inflammation.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Article
- Cannabinoid CBBritish journal of pharmacology · 2025Review
- Assessments of Evoked and Spontaneous Pain Following Administration of Gabapentin and the Cannabinoid CBbioRxiv : the preprint server for biology · 2025Article
- Microglial cannabinoid receptor type II stimulation improves cognitive impairment and neuroinflammation in Alzheimer's disease mice by controlling astrocyte activation.Cell death & disease · 2024Article
- Effects of the Dual FAAH/MAGL Inhibitor AKU-005 on Trigeminal Hyperalgesia in Male Rats.Cells · 2024Article
- Efficiency and safety of cannabinoid medical use: an analysis of discussions and observed trends on Instagram.Frontiers in public health · 2024Article
- Hydrogen Sulfide Interacting with Cannabinoid 2 Receptors during Sciatic Nerve Injury-Induced Neuropathic Pain.Antioxidants (Basel, Switzerland) · 2023Article
- The Selective CB2 Agonist COR167 Reduced Symptoms in a Mice Model of Trauma-Induced Peripheral Neuropathy through HDAC-1 Inhibition.Biomedicines · 2023Article
- Microglial Cannabinoid CBInternational journal of molecular sciences · 2023Review
- Endocannabinoid System: Chemical Characteristics and Biological Activity.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-retroviral toxic neuropathy.Pharmacological research · 2023Article
- The Roles of Imaging Biomarkers in the Management of Chronic Neuropathic Pain.International journal of molecular sciences · 2022Review
- TRPM8 contributes to sex dimorphism by promoting recovery of normal sensitivity in a mouse model of chronic migraine.Nature communications · 2022Article
- Review
- Operant Self-medication for Assessment of Spontaneous Pain Relief and Drug Abuse Liability in Mouse Models of Chronic Pain.Bio-protocol · 2022Article
- Contribution of CD4+ cells in the emotional alterations induced by endometriosis in mice.Frontiers in behavioral neuroscience · 2022Article
- Receptor mechanisms underlying the CNS effects of cannabinoids: CBAdvances in pharmacology (San Diego, Calif.) · 2022Article
- Cannabinoid CBFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 4 countries.
David CabañeroLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0002-1133-0908
Angela Ramírez-LópezLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Eva DrewsInstitute of Molecular Psychiatry, University of Bonn, Bonn, Germany.
Anne SchmöleInstitute of Molecular Psychiatry, University of Bonn, Bonn, Germany.
David M OtteInstitute of Molecular Psychiatry, University of Bonn, Bonn, Germany.
Agnieszka Wawrzczak-BargielaDepartment of Pharmacology, Laboratory of Pharmacology and Brain Biostructure, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.
Hector Huerga EncaboImmunology Unit, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Sami KummerLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Antonio Ferrer-MontielInstitute of Research, Development and Innovation in Healthcare Biotechnology of Elche (IDiBE), Universidad Miguel Hernández de Elche, Alicante, Spain.
Ryszard PrzewlockiDepartment of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.
Andreas ZimmerInstitute of Molecular Psychiatry, University of Bonn, Bonn, Germany.
Rafael MaldonadoLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0002-4359-8773
Universitat Pompeu Fabra · ESUniversity of Bonn · DEMaj Institute of Pharmacology · PLUniversitat de Miguel Hernández d'Elx · ES
Funding
European Commission FP7-602891-2Generalitat de Catalunya 2014-SGR-1547Generalitat de Catalunya 2018 FI_B 00207Generalitat de Catalunya SGR2017-669Instituto de Salud Carlos III RD12/0028/0023/FEDERInstituto de Salud Carlos III RTA, RD16/0017/0020Ministerio de Ciencia e Innovación SAF2017-84060-R-AEI/FEDER-UEMinisterio de Economía y Competitividad SAF2014-59648-PPolish Ministry of Science and Education 3070/7.PR/2014/2Spanish Ministry of Science, Innovation and Universities RTI2018-097189-B-C21Universidad Miguel Hernandez UMH-PAR2019
Abstract
Cannabinoid CB
Indexed as
AnimalsCannabinoid Receptor AgonistsCannabinoidsMaleMiceMice, Inbred C57BLMice, KnockoutMonocytesNeuralgiaNeuronsProtective AgentsRandom AllocationReceptors, CannabinoidSelf Administration1,1-dimethylbutyl-1-deoxy-Delta(9)-THCCannabinoid Receptor AgonistsCannabinoidsProtective AgentsReceptors, Cannabinoidcannabinoid cb2 receptorhuman biologymedicinemouseneuroimmune interactionsneuronal and lymphocyte cannabinoid receptorsneuropathic painneuroscienceoperant drug self-administrationspontaneous pain
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.